THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR ENALAPRIL IN ACUTE ISCHEMIC RENAL-FAILURE IN RATS

被引:11
|
作者
KOELZ, AM
BERTSCHIN, S
HERMLE, M
MIHATSCH, M
BRUNNER, FP
THIEL, G
机构
[1] UNIV BASEL, DEPT INTERNAL MED, CH-4051 BASEL, SWITZERLAND
[2] UNIV BASEL, DEPT PATHOL, CH-4051 BASEL, SWITZERLAND
[3] UNIV BASEL, DEPT RES, CH-4051 BASEL, SWITZERLAND
来源
EXPERIENTIA | 1988年 / 44卷 / 02期
关键词
D O I
10.1007/BF01952206
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The influence of the renin-angiotensin system on renal hemodynamics, tubular pressure and tubulo-glomerular feedback was investigated with the angiotensin converting enzyme inhibitor MK 421 (enalapril), in uninephrectomized rats with and without ischemia-induced acute renal failure. In animals with normal renal function proximal tubular pressure and tubulo-glomerular feedback response were lowered by enalapril long-term treatment, whereas glomerular filtration rate and renal blood flow were not influenced by the drug. After 45 and 70 minutes ischemia there was no difference between treated and untreated animals in the severely impaired glomerular filtration rate. Renal blood flow remained unaffected by the treatment. The histological damage due to ischemia (tubular casts, tubular necrosis and medullary capillary congestion) was not influenced by enalapril. As tubulo-glomerular feedback had been significantly inhibited during renin-angiotensin inhibition, its importance in mediating acute renal failure remains doubtful; other factors such as tubular obstruction and medullary congestion may be crucial.
引用
收藏
页码:172 / 175
页数:4
相关论文
共 50 条
  • [1] ACUTE RENAL-FAILURE (ARF) IN THE DOG - PROTECTION BY ANGIOTENSIN CONVERTING ENZYME-INHIBITOR (CEI)
    LINDNER, A
    CUTLER, RE
    KIDNEY INTERNATIONAL, 1979, 16 (06) : 785 - 785
  • [2] DIURETIC ACTION OF THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR, ENALAPRIL
    NAVIS, GJ
    DEJONG, PE
    DONKER, AJM
    VANDERHEM, GK
    DEZEEUW, D
    CLINICAL RESEARCH, 1985, 33 (02): : A529 - A529
  • [3] ENALAPRIL, A NONSULFHYDRYL ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    VLASSES, PH
    LARIJANI, GE
    CONNER, DP
    FERGUSON, RK
    CLINICAL PHARMACY, 1985, 4 (01): : 27 - 40
  • [4] ENALAPRIL - A NEW ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    WEINTRAUB, M
    EVANS, P
    HOSPITAL FORMULARY, 1985, 20 (07): : 796 - &
  • [5] ANTIHYPERTENSIVE EFFECT OF ENALAPRIL MALEATE, AN ANGIOTENSIN CONVERTING ENZYME-INHIBITOR, IN EXPERIMENTAL HYPERTENSIVE RATS
    IKEDA, N
    MAKI, E
    NARUSE, T
    ASAMI, T
    OHMURA, I
    FOLIA PHARMACOLOGICA JAPONICA, 1985, 86 (03) : P23 - P23
  • [6] EFFECTS OF A NEW ANGIOTENSIN CONVERTING ENZYME-INHIBITOR, ENALAPRIL, IN ACUTE AND CHRONIC LEFT-VENTRICULAR FAILURE IN DOGS
    LEDDY, CL
    WILEN, M
    FRANCIOSA, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 23 (5-6): : 189 - 198
  • [7] MATERNOTOXICITY AND FETOTOXICITY OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR, ENALAPRIL, IN RABBITS
    MINSKER, DH
    BAGDON, WJ
    MACDONALD, JS
    ROBERTSON, RT
    BOKELMAN, DL
    FUNDAMENTAL AND APPLIED TOXICOLOGY, 1990, 14 (03): : 461 - 470
  • [8] ENALAPRIL - A 2ND-GENERATION ANGIOTENSIN CONVERTING ENZYME-INHIBITOR
    BAJAJ, AK
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 296 (05): : 332 - 335
  • [9] ENALAPRIL - A LONG-ACTING ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR
    BOREK, M
    CHARLAP, S
    FRISHMAN, W
    PHARMACOTHERAPY, 1987, 7 (05): : 133 - 148
  • [10] REDUCED MYOCARDIAL EXPANSION WITH THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ENALAPRIL
    SHATKIN, BJ
    SWINFORD, RD
    HONIG, SC
    COHN, PF
    BROWN, EJ
    CIRCULATION, 1985, 72 (04) : 316 - 316